Peptide medicines and women's health

Peptide medicines are built from short chains of amino acids. Because many hormones in the body are themselves peptides, drug developers can design molecules that mimic or block those hormones with high specificity. In women's health, you will encounter several classes of peptide-based medicines, each tied to a different hormonal or metabolic pathway.

The GLP-1 receptor agonists and dual GIP/GLP-1 agonists-such as semaglutide and tirzepatide-mimic incretin hormones that regulate appetite and blood sugar. They are approved for type 2 diabetes and, at higher doses, for chronic weight management. GnRH agonists like leuprolide and GnRH antagonists like degarelix modify signaling from the hypothalamus and are used in hormone-driven conditions such as endometriosis and uterine fibroids. Teriparatide, a fragment of parathyroid hormone, is an anabolic osteoporosis treatment used in postmenopausal women at high fracture risk. Oxytocin, perhaps the most familiar peptide, is used in labor and postpartum care.

Why does any of this matter specifically for women? Hormonal environments change across the reproductive life span. Menstrual cycling, pregnancy, lactation, perimenopause, and menopause can alter metabolism, body composition, drug distribution, and organ function. A medicine studied mainly in men or postmenopausal women may not tell a reproductive-age woman what she needs to know.

Yet enrollment is only the first step. Many trials include women but do not report results separately by sex, or they report subgroup findings that were not planned in advance. Prespecified sex analysis-written into the trial protocol before data are collected-is stronger than a post-hoc look. Even then, a statistically significant subgroup result does not automatically mean a medicine works differently in women; the size of the subgroup and the width of the confidence interval matter.

When you read about a peptide medicine, look for three things: who was enrolled, whether sex-specific analyses were prespecified and adequately powered, and what the pregnancy and lactation label says. The U.S. FDA Pregnancy and Lactation Labeling Rule replaced old letter categories with narrative sections that explain risk summary, clinical considerations, and available data. For many newer peptide therapies, those sections describe limited human data and advise stopping the drug when pregnancy is recognized.

No article can replace a conversation with a licensed clinician. But knowing which questions to ask-about representation, analysis, and labeling-can make that conversation more productive.